| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 0.00 | 0.19 |
| Net Income | -18.30 | -25.74 |
| Diluted EPS | -7.43 | -10.60 |
- Net Income YoY
- +28.9%
Key highlights
- Net loss improved to $18.30 million in Q3 2026, compared to a $25.74 million loss in the prior year period
- Quarterly revenue decreased to $0.00 from $0.19 million in Q3 2025
- Management reaffirmed a cash runway projected to fund operations into late 2028
- Corporate restructuring and 60% workforce reduction expected to save $13.0 million annually
- Phase 2 EFZO-CONNECT topline results for efzofitimod remain on track for Q1 2027
How the Period Went
aTyr Pharma recorded a notable reduction in its net loss during the third quarter of 2026, reporting a deficit of $18.30 million. This figure represents a 28.9% improvement compared to the $25.74 million loss reported in the third quarter of 2025. Diluted earnings per share improved to -$7.43 from -$10.60 in the previous year's comparable period. Revenue for the quarter was $0.00, down from $0.19 million a year ago. This shift reflects the company's status as a clinical-stage biotechnology firm prioritizing long-term research over immediate commercial income, with the narrowing loss primarily attributed to a more disciplined approach to operational spending.
Margins and Profitability
The improvement in profitability metrics was largely driven by a strategic corporate restructuring. According to reports from stocktitan.net, the company initiated a 60% workforce reduction in August 2026, a move designed to lower annualized operating expenses by approximately $13.0 million beginning in the fourth quarter. Total assets decreased to $59.8 million as of September 30, 2026, down from $93.0 million at the end of 2025. This reduction was primarily due to the use of available-for-sale investments to fund clinical research. Despite the net loss, the company has managed to extend its liquidity, ensuring resources are concentrated on its lead therapeutic candidate.
Business Overview
aTyr Pharma is a clinical-stage biotechnology company developing first-in-class therapeutics based on its proprietary tRNA synthetase biology platform. The company's lead candidate, efzofitimod, is currently being evaluated for the treatment of interstitial lung disease (ILD), specifically focusing on systemic sclerosis and pulmonary sarcoidosis. By targeting the neuropilin-2 receptor, efzofitimod aims to modulate the immune system to treat chronic inflammatory and fibrotic conditions. As a clinical developer, the company currently maintains a $0 backlog, which is standard for firms in the pre-commercial phase of the drug development lifecycle as they await regulatory milestones.
Financial Context
- Management reported $50.3 million in cash and investments, which is projected to sustain operations into late 2028 per globenewswire.com.
- The consolidated net loss for the first nine months of 2026 improved to $39.4 million, down from $60.2 million in the prior year period.
- Market capitalization has stabilized at approximately $15.37 million, though the stock has faced a 71.5% decline over the last quarter.
- Current technical indicators show a Relative Strength Index (RSI) of 32.0, placing the stock near the oversold threshold.
- The company continues to transition away from higher-burn activities to prioritize the Phase 2 EFZO-CONNECT study results.
Down 13.1% since our story on 6 Nov: $6.03 when we broke it → $5.24 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $6.88 |
|---|---|
| 20 Oct | $6.92 |
| 21 Oct | $6.88 |
| 22 Oct | $6.80 |
| 23 Oct | $6.60 |
| 26 Oct | $6.12 |
| 27 Oct | $4.96 |
| 28 Oct | $5.12 |
| 29 Oct | $5.37 |
| 30 Oct | $4.94 |
| 2 Nov | $6.29 |
| 3 Nov | $6.63 |
| 4 Nov | $6.18 |
| 5 Nov | $6.03 |
| 6 Nov | $6.35 |
| 9 Nov | $7.58 |
| 10 Nov | $7.56 |
| 11 Nov | $6.77 |
| 12 Nov | $6.21 |
| 13 Nov | $6.11 |
| 16 Nov | $5.24 |
Industry Landscape
The biotechnology sector remains highly dependent on clinical milestones and capital preservation in 2026. aTyr Pharma’s focus on rare pulmonary diseases places it in a specialized niche where data readouts serve as primary valuation catalysts. Investors.atyrpharma.com reaffirmed that topline results from the Phase 2 study of efzofitimod in systemic sclerosis-related interstitial lung disease are expected in the first quarter of 2027. Peer comparisons in the micro-cap biotech space show similar trends of aggressive cost-cutting to bridge the gap toward late-stage clinical data, as access to capital remains sensitive to study results and regulatory clarity.
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 net lossSource: stocktitan.net | $-18.3 Million |
| 07 Aug 2026 | Q2 2026 net lossSource: investors.atyrpharma.com | $-10.3 Million |
| 15 May 2026 | Q1 2026 net lossSource: investors.atyrpharma.com | $-10.8 Million |
| 05 Mar 2026 | Q4 2025 net lossSource: investors.atyrpharma.com | $-14.0 Million |
| 06 Nov 2025 | Q3 2025 net lossSource: globenewswire.com | $-25.7 Million |
| 07 Aug 2025 | Q2 2025 net lossSource: investors.atyrpharma.com | $-19.5 Million |
| Share price | $6.03 |
|---|---|
| Market cap | $15M |
| Revenue (annual) | $190,000 |
| 1-month price change | -46.73% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by aTyr Pharma, Inc. announcing its third quarter 2026 financial results and operational updates.
Track aTYR PHARMA INC live
Get the next aTYR PHARMA INC SEC filing seconds after it lands.



